key: cord-0026869-9m0vj8qv
authors: Avdeef, Alex; Kansy, Manfred
title: Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE(Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression
date: 2022-02-07
journal: J Solution Chem
DOI: 10.1007/s10953-022-01141-7
sha: c9505e286e7fb0b4c48d2681385dfee2c9f28c4b
doc_id: 26869
cord_uid: 9m0vj8qv

This study applies the ‘Flexible-Acceptor’ variant of the General Solubility Equation, GSE(Φ,B), to the prediction of the aqueous intrinsic solubility, log(10) S(0), of FDA recently-approved (2016–2020) ‘small-molecule’ new molecular entities (NMEs). The novel equation had been shown to predict the solubility of drugs beyond Lipinski’s ‘Rule of 5’ chemical space (bRo5) to a precision nearly matching that of the Random Forest Regression (RFR) machine learning method. Since then, it was found that the GSE(Φ,B) appears to work well not only for bRo5 NMEs, but also for Ro5 drugs. To put context to GSE(Φ,B), Yalkowsky’s GSE(classic), Abraham’s ABSOLV, and Breiman’s RFR models were also applied to predict log(10) S(0) of 72 newly-approve NMEs, for which useable reported solubility values could be accessed (nearly 60% from FDA New Drug Application published reports). Except for GSE (classic), the prediction models were retrained with an enlarged version of the Wiki-pS(0) database (nearly 400 added log(10) S(0) entries since our recent previous study). Thus, these four models were further validated by the additional independent solubility measurements which the newly-approved drugs introduced. The prediction methods ranked RFR ~ GSE (Φ,B) > ABSOLV > GSE (classic) in performance. It was further demonstrated that the biases generated in the four separate models could be nearly eliminated in a consensus model based on the average of just two of the methods: GSE (Φ,B) and ABSOLV. The resulting consensus prediction equation is simple in form and can be easily incorporated into spreadsheet calculations. Even more significant, it slightly outperformed the RFR method.

In the 5-year period 2016-2020, 228 drugs were approved by the FDA, mostly for the treatment of cancer, infectious/viral diseases, and neurological disorders [1] [2] [3] [4] [5] [6] [7] . Of these drugs, 74% are 'small molecule' new molecular entities (NMEs). Many of the NMEs are larger, more lipophilic, and possess more H-bond acceptors, compared to older drugs in the Lipinski 'Rule of 5' (Ro5) chemical space [8, 9] . NMEs outside the Lipinski space are often dubbed 'beyond the Rule of 5' (bRo5) drugs [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Size inflation is not the only physicochemical characteristic of the NMEs. Some new drugs are relatively small.

Generally, large molecules may increase pharmacokinetic (PK) risks due to low solubility, possibly low cell permeability, increased efflux, and elevated metabolism. During drug discovery/early development, strategies to mitigate some of the risks have included: (i) selecting molecules which can dynamically form intramolecular H-bonds (IMHB) to shield polar groups, (ii) shielding polar groups by bulky side chains or by N-methylation, and (iii) selecting molecules with flexible rings structures [14] [15] [16] [17] [18] [19] . Flexible molecules with the potential to form IMHBs have been of particular interest, since these may possess enhanced solubility in water, by adopting hydrophilic 'extended' conformations, as well as facilitated permeability across cell membranes, by adopting hydrophobic 'folded' conformations [17] [18] [19] .

Solubility plays a central role in the fuller understanding of the PK risks. Reliable and actionable in silico models to predict solubility of NMEs and of promising molecules not yet synthesized, could be a valuable contribution to risk assessment [13] . We started to address this topic in a series of in silico studies [20] [21] [22] ; the present contribution is a continuation of that effort.

In a recent study to predict the intrinsic solubility, log 10 S 0 , of four standardized external test sets of mostly druglike molecules [20] , three methods were critically examined: (i) Yalkowsky General Solubility Equation (GSE) [23] , (ii) Abraham Solvation Equation (ABSOLV) [24] , and (iii) Breiman Random Forest regression (RFR) machine learning method [25] . RFR was found to be most accurate: for a highly-curated external test set of 100 druglike molecules with consistently-determined solubility values (average interlaboratory reproducibility, SD avg ~ 0.17 log 10 unit), the strength of the prediction was indicated by the coefficient of determination, r 2 = 0.64, and root-mean-square error, RMSE = 0.76 (log 10 unit) [20] . However, the 'black-box' machine learning RFR method has some disadvantages: (i) it does not directly suggest how compounds could be altered to increase/decrease their solubility [26] ; (ii) there is no obvious simple explicit equation to predict solubility which could be used in a spreadsheet calculation; (iii) the method 'learns' superlatively but 'teaches' tepidly. The linear ABSOLV model, based on Abraham's five solvation descriptors [24, 27] , yielded poorer statistics: r 2 = 0.26 and RMSE = 1.10 for the same test set. The GSE, Eq. 1, was even slightly less successful compared to ABSOLV (r 2 = 0.20, RMSE = 1.13) [20] . Nevertheless, the simple classic GSE is particularly appealing since it requires no 'training.' Merely the melting point (mp in o C) and the calculated (or measured) octanol-water partition coefficient, log P, are required to predict solubility (in log molar units):

In a follow-up study [21] , solubility prediction using the above three models was applied to large molecules (MW > 800 g·mol −1 ) . The novel aim was to explore to what extent Ro5 molecules could be used to predict the log 10 S 0 of molecules from the bRo5 space. For an external test set of 31 large molecules, RFR predicted solubility (r 2 = 0.37, RMSE = 1.07) better than the other two methods. The RFR results suggested that it was possible to develop a model trained on small Ro5 molecules to predict the solubility of large bRo5 molecules. Unfortunately, the 'how' was not explicitly obvious. Nevertheless, the RFR method could serve as a benchmark against which other more actionable models could be measured. Also, the study revealed that the traditional GSE systematically underpredicts solubility of poorly soluble (S 0 < 50 µmol·L −1 ) large molecules and greatly overpredicts solubility of highly soluble large molecules. The regression analysis of the three coefficients in Eq. 1 (0.5, − 1.0, − 0.01), using data partitioned into small and large molecule sets, resulted in notable differences between the two sets of coefficients, particularly in the first two terms (solvation contributions): (i) the 0.5 intercept in Eq. 1 was found to be − 0.28 for small molecules and − 1.77 for large molecules, and (ii) the log 10 P slope factor, − 1.0, changed from − 0.83 to − 0.40 in small to large molecules, respectively [21] . The ABSOLV equation (trained with small molecules) revealed a different pattern of largemolecule residuals from that of the GSE: the solvation equation underpredicted the solubility of every large molecule tested. This was especially evident for very flexible molecules (e.g., gramicidin A, bryamycin, and vancomycin). The principal components analysis of the solubility database used to train the models revealed an asymmetric distribution in the data, resembling the shape of a 'comet', with small molecules symmetrically occupying the 'head' and large molecules (MW > 800 g·mol -1 ) exclusively occupying the 'tail.' Two hallmarks of bRo5 chemical space reside in the tail [21] : large size and large number of H-bond acceptors (NHA).

The above study [21] and earlier investigations by Caron and coworkers [15] [16] [17] [18] 28] suggested that the influence of flexibility of large molecules on their solubility and permeability characteristics could be substantial. The latter researchers recommended the use of the Kier Φ molecular flexibility index [29] in modeling the properties of bRo5 molecules.

In our most recent solubility prediction study of bRo5 drugs, we discovered a way to incorporate the Kier molecular flexibility index, Φ, plus the Abraham B descriptor (H-bond acceptor strength) into Yalkowsky's classic GSE to improve its performance substantially [22] . The three coefficients in Eq. 1 were empirically determined as smooth functions (1) log 10 S GSE(classic)

of the sum descriptor, Φ + B. The modified equation was named the 'Flexible-Acceptor' model, GSE(Φ,B). It was trained with small (Ro5) molecules to predict the solubility of large (bRo5) molecules (not used in the training). With just three coefficients in Eq. 1, each defined as a three-parameter exponential function of Φ + B, the strength of prediction nearly matched that of the RFR machine learning method. The coefficient of log 10 P (traditionally fixed at -1.0) changed smoothly from − 1.1 for rigid nonionizable molecules (Φ + B = 0) to − 0.39 for typically flexible (Φ ~ 20, B ~ 6) large molecules. The intercept (usually fixed at + 0.5) varied smoothly from + 1.9 for rigid small molecules to − 2.2 for flexible large molecules. The mp coefficient remained practically constant, slightly different from the traditional value (− 0.01) for most molecules. For a test set of 32 large molecules the GSE(Φ,B) predicted the intrinsic solubility with RMSE of 1.10 log unit, compared to 3.0 by GSE(classic), and 1.07 by RFR.

Since our last study, it was found that the GSE (Φ,B) appears to work well not only for large drugs, but across a wide range of sizes of molecules. This piqued our interest to direct the new solubility prediction equation to recently-approved drugs (2016-2020), which comprise both the bRo5 and Ro5 molecules. For comparison, the GSE(classic), ABSOLV, GSE(Φ,B), and RFR models were each applied to predict the intrinsic solubility of 72 new drugs, for which useable reported solubility values could be accessed, nearly 60% from FDA published New Drug Application (NDA) reports [1] [2] [3] [4] [5] [6] [7] . The method performances ranked: RFR ~ GSE (Φ,B) > ABSOLV > GSE(classic). The performance of the GSE (Φ,B) was almost as good as that of the RFR. However, when the GSE (Φ,B) and ABSOLV methods were averaged, the resulting consensus model slightly outperformed the RFR method.

Yalkowsky and coworkers developed the General Solubility Equation (GSE), Eq. 1, to predict the solubility of liquid/solid nonelectrolytes (mostly industrial organic chemicals) in water [23, [30] [31] [32] [33] [34] [35] . The thermodynamic basis of the equation posits that the dissolution of a crystalline substance in water comprises two main contributions: (a) crystal lattice effect (XTL), related to the energy needed to break down the lattice to form a hypothetical 'supercooled liquid' (SCL), and (b) solvation effect, related to the energy released as the SCL dissolves in water. The total solubility of the compound in water is the product of the above two contributions, which in logarithmic terms can be stated as the sum [33, 34] 

The lattice contribution, log 10 S XTL W = −ΔS m T m − T 2.303RT , arises from the application of the van't Hoff equation, where ∆S m (kJ·mol -1 ·K -1 ) is the standard molar entropy of phase transformation and T m is the melting point (K). For many small organic compounds, ∆S m ≈ 0.057 kJ·mol -1 ·K -1 [33, 34] . Since at 25 °C, 2.303 RT = 5.7 kJ·mol -1 ·K -1 , Eq. 2 reduces to Eq. 3, where mp is the melting point in °C.

(2) log 10 S = log 10 S STL W + log 10 S SCL W

Hansch and coworkers [36] demonstrated that log 10 S of 156 simple liquid solutes correlated linearly with the octanol-water partition coefficients, log 10 P ≈ log 10 S liq oct S liq W . This led to the approximation:

where a 0 = log 10 S liq oct (solubility of a liquid solute in octanol) and a 1 ≈ − 1. For small alcohol, aromatic, and alkane solutes, the series-dependent a 0 intercepts were determined as: + 0.93, + 0.34, − 0.25, respectively. The a 1 slope factors varied less: − 1.1 (alcohols), − 1.0 (aromatics), and − 1.2 (alkanes).

Yalkowsky and coworkers surmised that a 0 = log 10 S SCL oct = 0.5 [23] . The entropy of mixing favors complete miscibility of the two liquids (liquid solute and octanol); i.e., the mole fraction = 0.5. Since the concentration of pure octanol is 6.32 mol·L −1 , then log 10 S liq oct = log 10 (6.32 × 0.5) = 0.5. With this approximation (and with a 1 = − 1), Eq. 4 substituted into Eq. 3 reduces to Eq. 1.

These fundamental considerations suggest that the traditional Eq. 1 could be adapted to compounds from the bRo5 chemical space, since Hansch's research hinted that the three coefficients in Eq. 1 could be optimized to different classes of compounds. If the 'supercooled liquid' form of a large polar solute is not fully miscible with octanol, then the log 10 S SCL oct contribution could very well be a negative number. Hence, a large molecule with a decreased S SCL oct (due to decreased miscibility) is expected to have an increased S SCL W . This, in effect, would lessen the contribution of lipophilicity to the predicted solubility.

In our earlier investigation [22] it was found that molecular flexibility (Φ) [29] could be incorporated into a nonlinear variant of the GSE to produce a promising trainable model with improved accuracy in predicting the solubility of large molecules (MW > 800 g·mol -1 ). Further incremental improvements were achieved with an augmented second descriptor: Abraham's H-bond basicity (B), a measure of H-bond acceptor potential [24, 27] . The derived GSE(Φ,B) has the general form, with the three c-coefficients treated as three-parameter exponential functions of (Φ + B):

(3) log 10 S = log 10 S SCL W − 0.01(mp − 25)

(4) log 10 S liq W = a 0 + a 1 log 10 P

The c-coefficients at aggregated values of Φ + B were determined by partial least squares (PLS open-source package from https:// cran.r-proje ct. org/ web/ packa ges/ pls) analysis of solubility data sorted on values of Φ + B and uniformly binned into groupings of 209-1384 points. The details of the PLS procedure have been already described [22] . Since our database of solubility values has increased in size since our last study and since the focus now is on new drugs rather than specifically on big drugs, a new set of b-constants was determined in the current investigation, using druglike molecules as the training set, but excluding new drugs from the training.

Kier [29] constructed (considering structural attributes such as counts of chains, rings, branches, and heavy atoms) the molecular flexibility index, Φ, as the product of first and second order 'kappa' shape indices, 1 k and 2 k, divided by the heavy atom count in the molecule. Here, values of Φ were calculated from the two kappa and the heavy atom count descriptors provided by the Landrum's RDKit open-source chemoinformatics library [37] . Table 1 lists these Φ values.

To account for the thermodynamics of solute transfer from one phase to another, Abraham [24, 27] introduced five solvation descriptors: A, B, S π , E, and V. Two of these constitute hydrogen bonding potential: A is the sum of H-bond acidity (donor strength) and B is the sum of H-bond basicity (acceptor strength) in the molecule. S π is the dipolarity/polarizability (subscripted so as not to confuse it with solubility), E is an excess molar refraction in units of (cm 3 ·mol −1 )/10, and V is the McGowan characteristic volume in units of (cm 3 ·mol −1 )/100. Since large molecules have greater number of H-bond acceptors, compared to small molecules [21] , the Abraham B descriptor was selected to augment the Φ descriptor to further improve solubility prediction in the bRo5 chemical space [22] . Values of the Abraham descriptors were calculated from 2D structures using the ABSOLV algorithm [27] (cf., www. acdla bs. com) and are listed in Table 1 for the new drugs.

Abraham and Le [24] amended the ABSOLV model to predict intrinsic solubility (log molar):

The independent variables are the five solute descriptors, plus the cross product of the H-bond terms. The seven d-coefficients were determined by PLS regression, using the training set database, exclusive of the new drugs set.

The implementation of the RFR open-source 'randomForest' library for the R statistical software has been described in our earlier solubility prediction studies [20] [21] [22] . The version used was downloaded from https:// www. stat. berke ley. edu/ ~breim an/ Rando mFore sts/ cc_ home. htm. The method works by constructing an ensemble of hundreds of decision trees employing about 200 RDKit-generated molecular descriptors. The same procedure was applied in the current study. The method was re-trained with the enlarged database, excluding the newly-approved drugs. Table 1 Physicochemical properties of newly approved drugs (2016-2020) 

The annual mini-reviews of FDA drug approvals by Mullard [1] [2] [3] [4] [5] Generally, there was virtually no experimental detail about the measurements in the published regulatory reports. Most of the reported solubility values are of drugs in water (S W ), without mention of the saturation pH. The temperature was assumed to be 23 °C when not stated or when reported as 'room temperature' (Table 1 ). In the dearth of experimental detail, it is a challenge to assess the quality of the reported measurements in most of the FDA/EMA/AUSPAR reports. Still, there are high quality data in some of the documents, where solubility measurements were published as a function of pH. Examples of some of these are presented below.

Of the 169 small-molecule NMEs approved in the 5-year period, 98 quantitative solubility measurements were found for only 72 NMEs . The reported values were transformed into the intrinsic solubility scale, S 0 , using known (or predicted) pK a values, and adjusted to 25 °C [116] using the program pDISOL-X (in-ADME Research) [117] [118] [119] [120] [121] [122] . Table 1 lists the normalized solubility data, along with the pK a values used in the data analysis.

The Wiki-pS 0 (in-ADME Research) intrinsic aqueous solubility database of mostly druglike molecules (currently with 7190 deeply-curated entries) was used to train the ABSOLV, GSE(Φ,B) and RFR models. Several hundred values from the database have already been published [20] [21] [22] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] , and the entire database is currently being prepared for publication as a book. The newly-approved drugs were used as external test sets and were excluded from the training process.

The structures of the 72 new drugs considered here (along with the year of approval) are shown in the Appendix (Fig. 9) . In dual-API drug products, each API was treated as a separate 'drug' in the data analysis.

Originally in Eq. 1, mp and log 10 P, were taken to be experimental values. However, it has become a common practice to use calculated values, clogP, in place of measured log 10 P. In this study, clogP values were in all cases calculated by the Wildman-Crippen sum of atomic contributions method in the open-source RDKit chemoinformatics library [37] .

Experimental mp values were employed where available and were calculated otherwise [127] . Values of mp are difficult to predict accurately. Prediction studies suggest rootmean-square error of about 35 °C. From this, the mp contribution to calculated log S could be uncertain by ~ 0.4 log 10 unit. Some uncertainty lingers even with tabulated experimental values, as it is sometimes unclear whether a particular mp value refers to a salt form or a free-acid/base form of the compound.

For half of the new drugs, log 10 S 0 values in Table 1 were determined from reported S W values, using pDISOL-X. The program also calculated the pH of the saturated solution, as though the Henderson-Hasselbalch (HH) equation were valid. When aggregates/complexes form or when supersaturation persists in the suspension, the HH equation does not accurately predict the shape of the log 10 S-pH curve [118] [119] [120] [121] [122] . There is no simple way to recognize such anomalies just from a single S W measurement. The remaining log 10 S data were sourced at two or more values of pH, which generally allowed for more confident determinations of log 10 S 0 . These 'raw' log 10 S-pH measurements required further data reduction and normalization. For ionizable molecules, the pK a values are required for such analysis. In cases where measured pK a values could not be found, they were calculated using the ChemAxon MarvinSketch v5.3.7 program (Che-mAxon Ltd., https:// www. chema xon. com), as indicated by italic values in Table 1 . In a few cases, it was possible to determine pK a values directly in the analysis of the log 10 S-pH profiles (bold values in Table 1) .

Examples of quality experimental log 10 S-pH profiles reported for some of the new drugs are shown in Fig. 1 . Frames a-c are of bases (acalabrutinib, pexidartinib, upadacitinib); frame d is that of an acid (dolutegravir); frame e is that of an ampholyte (talazoparib). The data from these five drugs appeared to follow shapes predicted by the Henderson-Hasselbalch equation: it was possible not only to determine the best-fit log 10 S 0 , but also the values of pK a (in five cases) and the pK sp (in two cases). When profiles deviate from expected shapes, it may be possible to assess (and to correct for) the degree to which the measurements may be supersaturated or if aggregates/complexes are forming [118] [119] [120] [121] [122] . Figure 1f (safinamide) shows such an example of anomaly, where at pH 4.5, the solubility is higher than that expected for a solution saturated in the free base. Since the solubility values at pH 1.2 and 4.5 are nearly the same, the suspension at pH 4.5 may have been supersaturated with respect to the charged form of the base during the measurement. Had only a single measurement been reported at pH 4.5, the intrinsic solubility might have been determined at an order of magnitude too high.

Training Set Figure 2 shows the distribution of intrinsic solubility values for the database training set and the NMEs test set. The new drugs on the average are nearly an order of magnitude less soluble. Figure 3 compares the properties used to evaluate whether a compound falls into Lipinski's 'Rule of 5' chemical space. The lipophilicities (as indicated by clogP) of the new drugs on the average are nearly an order of magnitude higher than those of the older drugs (Fig. 3a) . The mean molecular weight of the older drugs is just under 300 g·mol -1 ; it is 450 g·mol -1 for the new drugs (Fig. 3b) . Whereas the distribution of H-bond donors is nearly the same in the two sets (Fig. 3c) , the distribution of H-bond acceptors is quite (Fig. 3d) . On the average, the number of H-bond acceptors, NHA, is about 4 per molecule for older drugs and nearly 7 per molecule in the newly-approved drugs.

The new drugs violate the boundary conditions of Lipinski's Ro5 more often than those in the training set. There are relatively more molecules with clogP > 5 in the new drugs set (15% of NMEs), compared to that of the training set (6%). For the new drugs, 28% of the substances have MW > 500 g·mol -1 , compared to 7% in the training set. The relative number of NHD > 5 in the new drugs set (5%) is higher than in the training set molecules (2%). The relative number of NHA > 10 for the new drugs (9%) is greater than in the training set (3%).

The distributions of Φ values for the training and test sets are shown in Fig. 4 . On the average, the new drugs are more flexible (mean Φ = 6.2) than the molecules in the training set (mean Φ = 4.3). The training set spans a wide range of Φ values, from 0.4 to 43. The newly-approved drugs subtend that space, with Φ values ranging from 1.9 to 24.

The training set solubility data were sorted by Φ + B into ten bins of increasing values. For a narrow range of Φ + B values in each bin, the three GSE coefficients in Eq. 5 were determined by linear PLS regression, in the way that Hansch et al. [36] had trained the GSE for different chemical classes of compounds. Table 2 lists the set of determined c-constants for each of the bins. The resultant c-constants are depicted by the points on the three curves in Fig. 5 , displayed as a function of the average values of Φ + B from each bin. It is possible to recognize trends for the substantially decreasing c 0 , the steadily increasing c 1 , and the very slightly increasing c 2 coefficients with increasing values of Φ + B. Apparently, crystal lattice contributions are not appreciably affected by molecular flexibility and H-bond acceptor character, and trend near the traditional value (− 0.01) in Eq. 1. Evidently, solubility dependence on flexibility and H-bond acceptor strength are mediated by solution-phase interactions [26] . The bin analysis results are summarized in Table 2 .

From the thermodynamics considerations, the c 0 coefficient may be viewed as a measure of the solubility of the 'supercooled' liquid solute in octanol (c 0 ≈ log 10 S sliq oct ). Increasingly flexible molecules with strong H-bond acceptor character appear to be less (Table 2) . On the average, each bin contained about 700 log 10 S 0 measurements. For each bin (represented by a point in the plots), the three constants in Eq. 1 were determined by PLS regression to best fit the intra-bin solubility data. The aggregate intercept coefficient, c 0 (Φ,B) in Eq. 6, is described by an exponential decay function spanning from + 1.1 (rigid, octanol-miscible molecules) to − 3.4 (flexible, octanol-immiscible molecules).

In the next two frames, the coefficient functions, c 1 (Φ,B) in Eq. 7 and c 2 (Φ,B) in Eq. 8, are depicted by exponential rises to the limiting values − 0.27 (= − 1.369 + 1.099)) and − 0.52 (= − 1.128 + 0.608), respectively miscible with octanol, as suggested by the decreasing c 0 coefficients with increasing Φ + B (cf., Table 2 and Fig. 5 ). Between bins 1 and 10, S sliq oct decreases by four orders of magnitude. Given that the c 1 coefficient also changes with Φ + B, the precise thermodynamic interpretation of the c 0 coefficient is less clear than in the classical derivation [23, 33, 34] where c 1 is constant.

The points in Fig. 5 were fitted to exponential forms as functions of Φ + B to determine the b-parameters (Eqs. 6-8), using standard nonlinear least-squares methods. The resultant best-fit curves in Fig. 5 define the aggregated form of the GSE (Φ,B) , in the final form with the nine b-parameters determined, as shown below.

The d-coefficients in Eq. 9 were determined by PLS regression using the log 10 S 0 values from the Wiki-pS 0 database, excluding those of the NMEs: r 2 = 0.65, RMSE = 1.16, n = 7092. Figure 6 shows the results of the training of the four models, as measured log 10 S 0 vs. calculated log 10 S 0 correlation plots. The solid diagonals are identity lines. The dashed diagonals are ± 0.5 log 10 unit displaced from the identity lines. The measure of prediction performance (MPP) is indicated by the pie-charts as the percentage of predicted values that are within ± 0.5 log 10 unit of the observed values [128] . In the first three frames, the symbols represent the predominant charge states of molecules at pH 7.4: black diamonds represent uncharged molecules, blue squares represent bases (positive charged), red circles represent acids (negative charged), and yellow diamonds represent zwitterions. The zwitterions are less well predicted in the GSE model, compared to the ABSOLV model [20] . The Random Forest Regression (RFR) internal validation was applied to randomly-selected 30% of the database, based on training using the other 70% of the database (exclusive of new drugs). For molecules like those of the database, it is expected that their log 10 S 0 could be predicted with r 2 = 0.90, RMSE = 0.62, with 76% of the molecules 'correctly' predicted (Fig. 6d) . Generally, the other three methods are less precise, with MPP values ranging around half of the RFR value. Figure 7 shows the results of the predictions of the solubility of the newly-approved drugs (external test sets) by the four models. Table 3 summarizes the results. Briefly, the four results look similar, as MPP values range from 28 to 39%. Note that the horizontal scale in Fig. 7a is quite different from those of the other frames. The GSE(classic) underperformed compared to the other methods. The Flexible-Acceptor model produced prediction metrics nearly equal to those of RFR. None of the methods produced RMSE < 1, which may be indicative of the uncertain quality of half of the new drugs solubility data reported as single-point values in water. On the other hand, RFR uncharacteristically overpredicted the solubility of drugs with log 10 S 0 < 7, which may hint that those molecules possessed structural features not found in the Wiki-pS 0 training database. The GSE(Φ,B) also shows similar overpredictions.

The bias in the predicted results is near zero (− 0.06) in the RFR method. Both GSE methods show negative bias (− 0.33 and − 0.25), whereas the ABSOLV method produces a positive bias (+ 0.29). A consensus model was suggested by averaging the ABSOLV Fig. 6 Training set predictions of the four models considered: measured log 10 S 0 vs. calculated log 10 S 0 . The solid diagonals are identity lines. The dashed diagonals are ± 0.5 log 10 unit displaced from the identity lines. The pie-charts indicate the percentage of 'correctly' predicted values (see text). a GSE(classic) model, according to Eq. 1 (untrained). b ABSOLV model, Eq. 13, with coefficients determined by PLS regression. c Flexible-Acceptor GSE(Φ,B) model, according to Eqs. 10-12 (see text), and d Random Forest Regression (RFR) internal validation applied to randomly-selected 30% of the database, trained using the other 70% of the database and GSE(Φ,B), to minimize the method bias. Figure 8 shows the results of the consensus model. Although the r 2 (0.67) and RMSE (1.07) values in the consensus method match those of the RFR method, the MPP value (40%) and the bias (+ 0.02) in the consensus model are slight improvements.

The Wiki-pS 0 database of druglike molecules has steadily grown over the last 10 years. Lately, it has been our observation that this alone has not proportionately improved its ability to predict the solubility of drugs. Metrics such as those in Fig. 6 have remained largely unchanged [20] [21] [22] . Solubility prediction depends on multi-dimensional factors (quality of measurements of both training and test sets, distribution of training set molecules in chemical space in relation to the tested drugs, sensitivity of descriptors used in prediction models, etc.), with some factors yet to be recognized. Simply increasing the size of the solubility training set may not lead to improved predictions. Lipinski has suggested that compiling a large physicochemical property database aimed at maximizing chemical diversity may be an inefficient strategy for predicting the properties of novel molecules, given the enormous size of the chemical space, and since drugs appear to exist there as small tight clusters [129] . However, small improvement in solubility prediction can be expected as the training set acquires additional measurements of regulatory newly-approved molecules on a regular basis-i.e., drawing from the "tight cluster" space. It would be helpful if the quality of such measurements were to improve with time. New descriptors which can better differentiate the factors affecting solubility also can be important for narrowing the gap between the accuracy of the prediction models and that of the experimental data.

Many of the new drugs are large and fall outside of the Lipinski Ro5 chemical space, as depicted in Fig. 3 . It would have been helpful to have access to more quantitative solubility measurements of the newly-approved drugs than provided in the regulatory agency reports. The experimental uncertainty of nearly half of the new measurements could not be directly verified. If better practices in solubility measurement were adhered to, as detailed in the recent data-quality 'white paper' by experts from six countries [121] , and the experimental details were more openly shared, newly-reported measurements could achieve results with interlaboratory SD < 0.2 log 10 unit. But apparently this is work still in progress. The data quality in the curated database (SD < 0.2 log unit) used here as the training set is not the limiting factor in prediction, given that the best root-mean-square error achieved in this study was above a log unit. The benchmark statistical machine learning approaches are probably up to the task in narrowing the gap between prediction and measurement. The Flexible-Acceptor GSE(Φ,B) performed nearly as well as the benchmark Random Forest regression method in predicting the aqueous intrinsic solubility of the newly-approved drugs (2016-2020). A similar near-match had been previously reported by us in the prediction of the solubility of large (bRo5) drugs, supporting the general applicability of the Flexible-Acceptor model. A consensus model based on the average predictions of the ABSOLV and GSE(Φ,B) methods was found to reduce the prediction biases in the separate methods, but perhaps even more significant, it slightly outperformed the Random Forest regression method overall. The relatively-simple consensus model can be readily incorporated into spreadsheet calculations. 

FDA drug approvals. FDA approval count fell last year, despite a steady regulatory filing rate

FDA drug approvals. The FDA approved 46 new drugs last year, the highest total in more than two decades

FDA drug approvals. The FDA approved a record 59 drugs last year, but the commercial potential of these drugs is lackluster

FDA drug approvals. The FDA approved 48 new drugs last year, keeping up the momentum of recent years

FDA drug approvals. The FDA approved 53 novel drugs in 2020, the second highest count in over 20 years

in review: FDA approvals of new molecular entities

Properties of FDA-approved small molecule protein kinase inhibitors

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Molecular inflation, attrition & the rule of five

Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates

Cell permeability beyond the rule of 5

Beyond the rule of 5: lessons learned from AbbVie's drugs and compound collection

Computational prediction of formulation strategies for beyond-rule-of-5 compounds

When barriers ignore the rule-of-five

Experimental lipophilicity for beyond Rule of 5 compounds

Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space

Intramolecular hydrogen bonding: an opportunity for improved design in medicinal chemistry

Flexibility in early drug discovery: focus on the beyond-rule-of-5 chemical space

Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity

Prediction of aqueous intrinsic solubility of druglike molecules using random forest regression trained with Wiki-pS 0 database

Can small drugs predict the intrinsic aqueous solubility of 'beyond rule of 5' big drugs?

Flexible-acceptor general solubility equation for beyond rule of 5. Drugs

Solubility and partitioning I: Solubility of nonelectrolytes in water

The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship

Random forests

Why are some properties more difficult to predict than others? A study of QSPR models of solubility, melting point, and log P

Estimation of molecular linear free energy relation descriptors using a group contribution approach

Solubility prediction in the bRo5 chemical space: where are we right now?

An index of molecular flexibility from kappa shape attributes

Aqueous Solubility: Methods of Estimation for Organic Compounds

Comments on prediction of the aqueous solubility using the general solubility equation (GSE) versus a genetic algorithm and a support vector machine model

Prediction of drug solubility by the general solubility equation

Estimation of the aqueous solubility I: application to organic nonelectrolytes

Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE)

Estimation of the aqueous solubility of weak electrolytes

Linear free-energy relationship between partition coefficients and the aqueous solubility of organic liquids

Making sure there's a give associated with the take: producing and using open-source software in big pharma

Crystal forms of (S)-4-(8-Amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-A]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input

Novartis pharmaceuticals NDA 212526Orig1s000

Multi disci plineR. pdf

European Medicines Agency: Apalutamide (Erleada®), CHMP assessment report

Crystal structures and physicochemical properties of amisulpride polymorphs

Solubility determination and modeling for artesunate in binary solvent mixtures of methanol, ethanol, isopropanol, and propylene glycol + water

Food and Drug Administration (USA): Avapritinib (Ayvakit), Blueprint meds. Corp. 2019 NDA 212608Orig1s000

Safety Data Sheet: Baloxavir marboxil (Xofluza)

Food and Drug Administration (USA): Baloxavir marboxil (Xofluza)

Improving the solubility of the antichagasic drug benznidazole through formation of inclusion complexes with cyclodextrins

Proprietary Product Name: Briviact. Sponsor: UCB Australia Pty Ltd

Novartis Ringaskiddy Pharma Ltd

Decitabine + Cedazuridine (Inqovi)

Food and Drug Administration (USA): Cenobamate (Xcopri), SK Life Science, Inc. NDA 212839Orig1s000

Formulations of copanlisib. Bayer Pharma AG Patent Application Publication

In vitro skin retention of crisaborole after topical application

Product Monograph: Dacomitinib (Vizimpro)

Food and Drug Administration (USA): Darolutamide (Nubeqa), Bayer HealthCare Pharmaceuticals Inc. NDA 212099Orig1s000

Food and Drug Administration (USA): Dolutegravir <GSK1349572A>, GSK. 211994Orig1s000

Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system

In vitro evaluation of the drug interaction potential of doravirine

Hydroxypropyl-sulfobutylβ-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes

Development of a novel oral delivery system of edaravone for enhancing bioavailability

Preparation and physicochemical characteristics of the complex of edaravone with hydroxypropyl-?-cyclodextrin

European Medicines Agency: Zepatier® (elbasvir / grazoprevir) CHMP assessment report

Product Monograph: Enasidenib mesylate (Idhifa). Accessed

Genentech NDA 212725Orig1s000 & 212726Orig1s000

Food and Drug Administration (USA): Erdafitinib(Balversa), Jansseb Biotech Inc. NDA 212018Orig1s000

Food and Drug Administration (USA): Fedratinib (Inrebic), Impact Biomedicines, Inc. NDA 212327Orig1s000

Highlights of Prescribing Information: Fosnetupitant Dihydrochloride (in AKYNZEO)

Food and Drug Administration (USA): Gilteritinib (Xospata)

Highlights of prescribing information: Glasdegib (Daurismo)

Istradefylline (Nourianz), Kyowa Kirin, Inc. NDA 022075Orig1s000

The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals

Drug Approvals International

Food and Drug Administration (USA): Lonafarnib (Zokinvy)

NDA 205598Orig1s000, CDER Quality Assessment Review. Applicant: Aeterua Zentaris

Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency

Measurement and correlation of solubility of meropenem trihydrate in binary (water + acetone/tetrahydrofuran) solvent mixtures

Highlights of prescribing information: Moxidectin (Daurismo)

Food and Drug Administration (USA): Naldemedine (Symproic). NDA 208854Orig1s000, CDER Quality Assessment Review. Applicant: Shionogi Inc. 13

Puma Biotechnology, Inc. Highlights of prescribing information: Neratinib (Nerlynx)

Bayer Healthcare Pharmaceuticals, Inc. NDA 213464Orig1s000

Highlights of prescribing information: Niraparib (Zejula)

Celgene Corp

Food and Drug Administration (USA): Pemigatinib(Pemazyre), Incyte Corp. 2019 NDA 213736Orig1s000

Daiichi Sankyo Inc. NDA 211810Orig1s000

Multi disci plineR. pdf

Bioprojet Pharma NDA 211150Orig1s000

Blueprint Medicines Corp. NDA 213721. Product Quality Review(s). 5

Food and Drug Administration (USA): Pretomanid, The Global Alliance for TB Drug Development. NDA 212862Orig1s000

Relugolix (Orgovyx®) Myovant Sciences, Inc. label

Two polymorphs of remdesivir: crystal structure, solubility, and pharmacokinetic study

Hydrobromate of benzodiazepine derivative, preparation method and use thereof

Novel pieces for the emerging picture of sulfoximines in drug discovery: synthesis and evaluation of sulfoximine analogues of marketed drugs and advanced clinical candidates

Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations

Food and Drug Administration (USA): Ripretinib (Qinlock), Deciphera Pharmaceuticals, LLC. 2020 NDA 213973Orig1s000

Safety Data Sheet: Risdiplam (Evrysdi)

Food and Drug Administration (USA): Safinamide (Xadago)

Food and Drug Administration (USA): Secnidazole (Solosec)

Physico-chemical and solid-state characterization of secnidazole

Food and Drug Administration (USA): Selinexor (Xpovio), Karyopharm Therapeutics Inc. NDA 212306Orig1s000

Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic HCV NS5A inhibitor, in healthy subjects

Food and Drug Administration (USA): Selumetinib <Koselugo>, AstraZeneca NDA213756O-rig1s000

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

European Medicines Agency: Epclusa? (sofosbuvir/velpatasvir)

Stiripentol (Diacomit)

Food and Drug Administration (USA): Talazoparib (Talzenna)

Epizyme 2019 NDA 211723Orig1s000

Drug Approvals International: Tecovirimat (TPOXX)

Food and Drug Administration (USA): Tenapanor(Ibsrela), Ardelyx, Inc. NDA 211801Orig1s000

Food and Drug Administration (USA): Tezacaftor (Trikafta), Vertex Pharmaceuticals, Inc. NDA 210491Orig1s000

Food and Drug Administration (USA): Tucatinib <Tukysa>, Seattle Genetics. NDA213411O-rig1s000

Accessed 113. Food and Drug Administration (USA): Venetoclax <Venclexta>

Urovant Sciences, Inc. NDA 213006. Product Quality Review(s)

Food and Drug Administration (USA): Zanubrutinib (Brukinsa), BioGene USA. NDA 213217Orig1s000

Solubility temperature dependence predicted from 2D structure

Salt solubility products of diprenorphine hydrochloride, codeine and lidocaine hydrochlorides and phosphates-novel method of data analysis not dependent on explicit solubility equations

Anomalous solubility behavior of several acidic drugs

Phosphate precipitates and water-soluble aggregates in re-examined solubility-pH data of twenty-five basic drugs

Solubility-pH profile of desipramine hydrochloride in saline phosphate buffer: enhanced solubility due to drug-buffer aggregates

Equilibrium solubility measurement of ionizable drugs-consensus recommendations for improving data quality

Perspectives in solubility measurement and interpretation

Absorption and Drug Development

Multi-lab intrinsic solubility measurement reproducibility in CheqSol and shake-flask methods

Solubility challenge revisited after ten years, with multi-lab shake-flask data, using tight (SD ∼ 0.17 log) and loose (SD ∼ 0.62 log) test sets

Findings of the second challenge to predict aqueous solubility

ONS Melting Point Model 010. QsarDB content. Property mpC

Findings of the challenge to predict aqueous solubility

Drug-like properties and the causes of poor solubility and poor permeability

Do you know your r 2 ? ADMET& DMPK

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgements This study is dedicated to the memory of Professor Michael Abraham, whose pioneering work in the critical role of hydrogen bonding in solvation has influenced the authors deeply. He is remembered as a teacher and a friend. The complete Wiki-pS 0 database is planned to be released in book form: A. Avdeef. Intrinsic Aqueous Solubility-Curated Data for Pharmaceutical Research (under discussion with publisher).

The structures of the 72 newly-approved drugs, along with the year of approval, are shown in Fig. 9 Funding This study was self-funded. The authors declare that they have no known competing financial interests that could have appeared to influence the work reported in this paper.